1.
|
15 p, 4.5 MB |
Minimum Information about T Regulatory Cells : A Step toward Reproducibility and Standardization
/
Fuchs, Anke (Technische Universität Dresden, Germany) ;
Gliwiński, Mateusz (Medical University of Gdańsk, Poland) ;
Grageda, Nathali (MRC Centre for Transplantation, King's College London, Guy's Hospital) ;
Spiering, Rachel (Newcastle University) ;
Abbas, Abul K. (University of California, San Francisco) ;
Appel, Silke (University of Bergen, Norway) ;
Bacchetta, Rosa (Stanford School of Medicine, United States) ;
Battaglia, Manuela (San Raffaele Hospital, Milan) ;
Berglund, David (Uppsala University, Sweden) ;
Blazar, Bruce (University of Minnesota, United States) ;
Bluestone, Jeffrey A. (University of California, San Francisco, United States) ;
Bornhäuser, Martin (Technische Universität Dresden, Germany) ;
ten Brinke, Anja (University of Amsterdam) ;
Brusko, Todd M. (University of Florida Diabetes Institute) ;
Cools, Nathalie (University Hospital Antwerp (Bèlgica)) ;
Cuturi, Maria Cristina (Université de Nantes) ;
Geissler, Edward (University Hospital Regensburg, Germany) ;
Giannoukakis, Nick (Carnegie Mellon University, Pittsburgh, United States) ;
Gołab, Karolina (The University of Chicago, United States) ;
Hafler, David A. (Yale School of Medicine, New Haven, United States) ;
van Ham, S. Marieke (University of Amsterdam) ;
Hester, Joanna (University of Oxford) ;
Hippen, Keli (University of Minnesota, United States) ;
Di Ianni, Mauro (University of Chieti-Pescara) ;
Ilic, Natasa (University of Belgrade) ;
Isaacs, John (National Institute for Health Research Newcastle Biomedical Research Centre at Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University) ;
Issa, Fadi (University of Oxford) ;
Iwaszkiewicz-Grzes, Dorota (Medical University of Gdańsk, Poland) ;
Jaeckel, Elmar (Department of Gastroenterology, Hepatology, Endocrinology, Diabetology, Transplantationsforschungszentrum, Medical School of Hannover (MHH)) ;
Joosten, Irma (Laboratory of Medical Immunology, Department of Laboratory Medicine, Radboudumc, Netherlands) ;
Klatzmann, David (Hôpital Pitié-Salpêtrière, Paris) ;
Koenen, Hans (Laboratory of Medical Immunology, Department of Laboratory Medicine, Radboudumc, Netherlands) ;
van Kooten, Cees (Leiden University Medical Center, Netherlands) ;
Korsgren, Olle (Gothenburg University, Sweden) ;
Kretschmer, Karsten (University Hospital and Medical Faculty Carl Gustav Carus of TU Dresden, Germany) ;
Levings, Megan (The University of British Columbia, Vancouver, Canada) ;
Marek-Trzonkowska, Natalia Maria (Medical University of Gdańsk, Poland) ;
Martinez-Llordella, Marc (King's College London) ;
Miljkovic, Djordje (University of Belgrade) ;
Mills, Kingston H. G. (Trinity College Dublin, Ireland) ;
Miranda, Joana P. (Universidade de Lisboa) ;
Piccirillo, Ciriaco A. (Research Institute of McGill University Health Centre, Montréal, Canada) ;
Putnam, Amy L. (University of California, San Francisco) ;
Ritter, Thomas (National University of Ireland) ;
Roncarolo, Maria Grazia (Division of Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, ISCBRM, Stanford School of Medicine) ;
Sakaguchi, Shimon (Osaka University, Japan) ;
Sánchez-Ramón, Silvia (Hospital Clínico San Carlos (Madrid)) ;
Sawitzki, Birgit (Humboldt-Universität zu Berlin) ;
Sofronic-Milosavljevic, Ljiljana (University of Belgrade) ;
Sykes, Megan (University of California, San Francisco) ;
Vives Pi, Marta (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Waldmann, Herman (University of Oxford) ;
Witkowski, Piotr (The University of Chicago) ;
Wood, Kathryn J. (University of Oxford) ;
Gregori, Silvia (San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), San Raffaele Scientific Institute IRCCS) ;
Hilkens, Catharien M. U. (Newcastle University) ;
Lombardi, Giovanna (MRC Centre for Transplantation, King's College London, Guy's Hospital) ;
Lord, Phillip (School of Computing, Newcastle University) ;
Martinez-Caceres, Eva Maria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Trzonkowski, Piotr (Medical University of Gdańsk, Poland)
Cellular therapies with CD4+ T regulatory cells (Tregs) hold promise of efficacious treatment for the variety of autoimmune and allergic diseases as well as posttransplant complications. Nevertheless, current manufacturing of Tregs as a cellular medicinal product varies between different laboratories, which in turn hampers precise comparisons of the results between the studies performed. [...]
2018 - 10.3389/fimmu.2017.01844
Frontiers in immunology, Vol. 8 (january 2018)
|
|
2.
|
22 p, 2.2 MB |
Paving the way towards an effective treatment for multiple sclerosis : advances in cell therapy
/
Mansilla Lopez, Maria Jose (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Presas Rodríguez, Sílvia (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Teniente Serra, Aina (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
González-Larreategui, Íñigo (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Quirant, Bibiana (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Fondelli, Federico (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Djedovic, Neda (University of Belgrade. Department of Immunology) ;
Iwaszkiewicz-Grzes, Dorota (Poltreg S.A., Gdańsk, Poland) ;
Chwojnicki, K. (Medical University of Gdańsk. Department of Anaesthesiology & Intensive Care) ;
Miljković, Đ. (University of Belgrade. Department of Immunology) ;
Trzonkowski, P. (Poltreg S.A., Gdańsk, Poland) ;
Ramo-Tello, Cristina (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Martínez Cáceres, Eva María (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia)
Multiple sclerosis (MS) is a leading cause of chronic neurological disability in young to middle-aged adults, affecting ~2. 5 million people worldwide. Currently, most therapeutics for MS are systemic immunosuppressive or immunomodulatory drugs, but these drugs are unable to halt or reverse the disease and have the potential to cause serious adverse events. [...]
2021 - 10.1038/s41423-020-00618-z
Cellular and Molecular Immunology, Vol. 18 (may 2021) , p. 1353-1374
|
|